Novartis AG: insider trades · Switzerland · SIX SER

About Novartis AG

Novartis AG is one of the world’s leading innovative medicines companies and a core blue-chip name on the Swiss market, listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland. The group was formed in 1996 through the merger of Ciba-Geigy and Sandoz, and it remains headquartered in Basel, the historic center of its scientific and corporate identity. That Swiss origin still matters: Novartis combines a strong domestic base with a genuinely global operating footprint. The company’s business model is centered on discovering, developing, manufacturing, and commercializing prescription medicines with high medical value. Novartis focuses on major therapeutic areas where unmet need remains significant, notably oncology, immunology, cardiovascular, renal and metabolic diseases, and neuroscience. Beyond therapeutic franchises, the group has built technology capabilities in small molecules, biologics, xRNA, radioligand therapy, and gene and cell therapy. This gives Novartis a differentiated innovation platform and supports a portfolio that is less dependent on any single product cycle. Its commercial portfolio includes several well-known brands, such as Cosentyx in immune-mediated inflammatory diseases, Entresto in cardiology, Kisqali in oncology, Xolair in allergy and immunology, Leqvio for LDL-cholesterol reduction, Fabhalta in selected kidney diseases, and Pluvicto in radioligand therapy. More recently, the company has added or expanded newer assets such as Rhapsido and Itvisma. From an equity research perspective, this mix of established blockbusters and pipeline-driven launches is central to the investment case, because it supports both cash generation and medium-term growth optionality. Geographically, Novartis sells its medicines in more than 100 countries and operates a broad network spanning research, manufacturing, and distribution. The United States is a major commercial market, but Switzerland remains strategically important for governance, R&D, and corporate heritage. Recent corporate and regulatory news has been supportive: in 2025 Novartis secured FDA approvals for Rhapsido, Vanrafia, Pluvicto in an earlier treatment setting, and Itvisma, while also expanding the label for Leqvio. The company also agreed to acquire Anthos Therapeutics to strengthen its late-stage cardiovascular pipeline. For international investors, Novartis stands out as a large-cap healthcare compounder with a defensive earnings profile, a deep innovation pipeline, and a prominent listing on the SIX Swiss Exchange (SMI/SPI) in Switzerland.